会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • PTEFB-INHIBITOR-ADC
    • PTEFB抑制剂的ADC
    • WO2017060322A3
    • 2017-05-18
    • PCT/EP2016073825
    • 2016-10-06
    • BAYER PHARMA AG
    • WASNAIRE PIERREGRIEBENOW NILSBÖHNKE NIELSLÜCKING ULRICHLERCHEN HANS-GEORGSTELTE-LUDWIG BEATRIXMAHLERT CHRISTOPHBÖMER ULFGREVEN SIMONEDIETZ LISATERJUNG CARSTENZHENG KUNZENGPING GAOCHEN GANGXI JIAJUN
    • A61K47/68A61P35/00C07D498/08
    • C07D498/18A61K47/6803A61K47/6849A61K47/6851A61K47/6857A61K47/6863
    • It is an object of the present invention to provide substances which, after administration at a relatively low concentration, unfold apoptotic action and may therefore be of benefit for cancer therapy. To achieve this object, the invention provides conjugates of a binder or derivatives thereof with one or more active compound molecules, the active compound molecule being a CDK9 inhibitor attached to the binder via a linker L. The binder is preferably a binder protein or peptide, particularly preferably a human, humanized or chimeric monoclonal antibody or an antigen-binding fragment thereof, in particular an anti-TWEAKR antibody or an antigen-binding fragment thereof or an anti-EGFR antibody or an antigen-binding fragment thereof. Particular preference is given to an anti-TWEAKR antibody which binds specifically to amino acid D in position 47 (D47) of TWEAKR (SEQ ID NO: 169), in particular the anti-TWEAKR antibody TPP-2090, or the anti-EGFR antibodies cetuximab, TPP-4030, TPP-5653, or nimotuzumab. The inventors have found a number of ways to attach the binder to the CDK9 inhibitor in order to achieve the object mentioned above.
    • 本发明的一个目的是提供在相对低浓度施用后展现凋亡作用并因此可能对癌症治疗有益的物质。 为了实现该目的,本发明提供了粘合剂或其衍生物与一种或多种活性化合物分子的缀合物,活性化合物分子是通过连接物L连接至粘合剂的CDK9抑制剂。粘合剂优选为结合蛋白或肽, 特别优选人类,人源化或嵌合单克隆抗体或其抗原结合片段,特别是抗TWEAKR抗体或其抗原结合片段或抗EGFR抗体或其抗原结合片段。 特别优选抗TWEAKR抗体,其特异性结合TWEAKR(SEQ ID NO:169)的位置47(D47)中的氨基酸D,特别是抗TWEAKR抗体TPP-2090或抗EGFR抗体 西妥昔单抗,TPP-4030,TPP-5653或尼妥珠单抗。 发明人已经发现了许多将粘合剂附着到CDK9抑制剂上的方法,以达到上述目的。